[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
July 24/31, 2013

Black-White Differences in Breast Cancer Outcomes Among Older Medicare BeneficiariesDoes Systemic Treatment Matter?

Author Affiliations
  • 1Cancer Prevention and Control Program, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
  • 2Breast Cancer Program, Georgetown Lombardi Comprehensive Cancer Center
  • 3Departments of Medicine and Epidemiology and the Herbert Irving Comprehensive Cancer Center–Columbia University, New York, New York
JAMA. 2013;310(4):376-377. doi:10.1001/jama.2013.8273

Prior to the 1980s, there were minimal differences between blacks and whites in breast cancer mortality after adjustment for differences in incidence. There also were few available breast cancer treatments other than radical surgery. Black-white mortality differences in breast cancer mortality emerged in the United States in the late 1980s, with the advent of adjuvant systemic therapies and mammography, and they persist to the present.1 These trends suggest that, unless the underlying biology of breast cancer has changed differentially by race over time, the majority of disparities are likely to be related to variations in the use and quality of screening and adjuvant treatment. Although a large body of research has sought the reasons for any such differences, most investigations have not included representative US population samples or could not quantify the separate and combined contributions of multiple factors to observed disparities.

First Page Preview View Large
First page PDF preview
First page PDF preview
×